Deal Watch: Shire Increases Rare Disease Holdings, Abbott Expands Latin American Interests
MedImmune and Bristol announce immuno-oncology combination trials with new partners on the same day, while AC Immune and Piramal Imaging will collaborate to develop an Alzheimer’s diagnostic to trace abnormal Tau protein in neuronal tissue.
You may also be interested in...
The Swiss biotech raises $22 million in a Series D from its existing private investors to support its research into Alzheimer’s disease therapies.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Alexion/AstraZeneca has announced positive top-line results from the Phase III study of ALXN1840 in patients with the rare genetic disorder, Wilson disease, including in patients already on standard-of-care therapies. The compound is ahead of two candidate gene therapies from other companies at early-stage clinical development.